The Turkish Journal of Gastroenterology’s Post

<Editorial>#livercancer #HCC #Meded #chronicliverdisease #HCCscreening #diagnosis #whole-course management 💡 Whole-process management of HCC: before treatment, during treatment, and after treatment. Hepatoma Research   "Interpretation of Chinese expert consensus on the whole-course management of hepatocellular carcinoma (2023 edition)"   🔵 Early screening and diagnosis 🔵 Development of treatment plan 🔵 Safety monitoring 🔵 Follow-up   May we expect to hear your opinion on the whole-course management of hepatocellular carcinoma?   Full Text for free: https://lnkd.in/ggfppa6c

Overall survival results were published from KEYNOTE-564.  This was a phase III trial comparing 1 year of adjuvant pembrolizumab vs placebo in high risk clear cell renal cell carcinoma after surgical resection.  The trial demonstrated a HR of 0.62 (0.44-0.87; p=0.005).  Another positive from this data is that the survival curves continue to separate after completion of pembrolizumab, showing that adjuvant treatment does not only delay time to recurrence, and has a long-term benefit.   Overall survival at 48 months was 91.2% in the pembrolizumab group and 86.0% in the placebo group, so around 1 in 20 patients benefited from the addition of this therapy.  It is important not to extrapolate these results to a lower-risk population, as that may be one of the reasons why adjuvant nivoluamb failed in renal cell carcinoma (CheckMate 914).  Given the clear overall survival benefit, we should be giving 1 year of pembrolizumab in all high risk patients after resection. #keytruda #kidneycancer https://lnkd.in/e9yVhiV8

Inhibition of interleukin-1 signaling, but not tumor necrosis factor-α neutralization, improves myocardial dysfunction, and arrhythmias in Lactobacillus casei cell wall extract–induced #Kawasaki disease murine model. 🔗https://lnkd.in/dJkW2qmc

🚨🚨 #MAFLD  MAFLD-related hepatocellular carcinoma 🆕 meta-analysis; 56,565 individuals with HCC. 📌Total MAFLD HCC prevalence : 48.7% 📌Single MAFLD HCC prevalence: 12.4%. ➡️ MAFLD is common as a sole aetiology, but more so and as a co-factor in mixed-aetiology HCC

New study published this month on Hepatocellular Carcinoma (HCC): High METTL13 expression correlates with worse prognosis and has moderate diagnostic value for early HCC. 🧬🔬 https://lnkd.in/dXeNGEYZ #TurkishJournalofGastroenterology #TJG #GastroenterologyResearch #MedicalJournals #GastrointestinalResearch #May #NewIssue #HCC #CancerResearch #Bioinformatics #NewStudy #Biomarker

One of the best aspects of clinical research is that when it goes beyond answering research questions: In Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC). Analysis did not stop in overall survival for all subgroups. Analysis answers the important question: What happened to those patients who had disease progression on STRIDE protocol ? They had the worst prognosis and worst overall survival, even after stopping treatment and having new subsequent lines. this means that the next step is to investigate the causes of failure for those patients who have resistant HCC clones to many lines of treatment. Lorenza Rimassa : thanks for your fruitful interactive discussion #HCC #STRIDE #Durvalumab #HIMALAYA

In this informative new piece on OncLive, Dr. Joseph Franses talks about 2nd line treatment options for hepatocellular carcinomas-- read/listen at https://lnkd.in/g2GqMXFQ !!

#HighlyCitedPapers   📝 First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination — Tella, Kommalapati, Mahipal and Jin.   In this paper, the authors outlined the tumorigenesis and immune landscape of hepatocellular #carcinoma in brief and discussed the role and rationale of combining immunotherapy and anti-VEGF therapy.   Full text is available 👇 https://lnkd.in/dhFsJZPX   #medicine #health #research #science

Summary: The article explores the use of Pholiota adiposa polysaccharide-coated selenium nanoparticles for immunotherapy against hepatocellular carcinoma by reversing M2-like tumor-associated macrophage polarization. The study demonstrates the development of a stable nanodrug, PAP-SeNPs, with dual anti-tumor and immune stimulation effects that could potentially serve as a therapeutic agent for both the prevention and treatment of HCC. Additionally, the research delves into the mechanism of macrophage polarization by PAP-SeNPs, indicating promising outcomes in combating hepatoma growth. Hashtags: #HCC #immunotherapy #biohacking #macrophages #nanotechnology Read more here: https://lnkd.in/ejVtJn3g BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.

📢 Enhancing Pituitary Gland Tumor Diagnosis with BioGenex's IHC Panels 🧬 Pituitary gland tumors can significantly impact hormonal balance and health. BioGenex leads in advancing diagnostic tools for early detection and accurate diagnosis of these tumors, including rare pituitary carcinomas. 🔬 Key Markers in Our IHC Panel: Anti-FSH-BETA: Identifies Follicle Stimulating Hormone (FSH) to differentiate pituitary adenomas. Anti-ACTH: Specifically identifies corticotroph adenomas, aiding in diagnosing Cushing’s disease. Anti-PIT-1: Diagnoses and differentiates pituitary adenomas. Anti-Prolactin: Detects prolactin-secreting cells, confirming prolactinomas. Markers like Ki-67 and P53 assess aggressiveness and recurrence potential. BioGenex offers RTU and concentrated antibodies for manual and automated systems, optimizing clinicopathological diagnosis and drug discovery. 🎯 Our Commitment: Early Detection and Accurate Diagnosis High-Quality, Diverse Antibodies Ready-to-use and Concentrated Formats Join us in advancing healthcare with cutting-edge diagnostic solutions. 🩺 Learn More: https://hubs.la/Q02JJ9SV0 🔍 #BioGenex #PituitaryTumor #IHC #CancerDiagnostics #HealthcareInnovation